Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Accid Anal Prev ; 133: 105271, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31586823

ABSTRACT

While there has been increasing interest in wet-weather pavement markings due to their improved visibility and potential for enhancing road safety in wet-night conditions, there is a lack of research evaluating their safety effectiveness based on actual wet-night crash data. This paper presents the safety assessment of wet-weather pavement markings in the Atlanta District of the Texas Department of Transportation, conducted by two different evaluation approaches that are known to be rigorous and statistically defensible: Empirical-Bayes before-after analysis and full Bayes before-after analysis with comparison groups. The results from both approaches suggest that there are positive safety effects of wet-weather pavement markings for relevant crashes, providing evidence-based support for safety benefits of wet-weather markings.


Subject(s)
Accidents, Traffic/statistics & numerical data , Weather , Accidents, Traffic/prevention & control , Bayes Theorem , Built Environment/standards , Humans , Safety
2.
Transl Psychiatry ; 8(1): 206, 2018 10 04.
Article in English | MEDLINE | ID: mdl-30287828

ABSTRACT

Agonists of the γ-aminobutyric acid (GABA) type A benzodiazepine (BZD) receptor exert anxiolytic effects in anxiety disorders, raising the possibility that altered GABA-ergic function may play a role in the pathophysiology of anxiety disorders, such as post-traumatic stress disorder (PTSD). However, few neuroimaging studies have assessed the function or binding potential of the central GABAA BZD receptor system in PTSD. Therefore, our aim was to compare the BZD receptor binding potential between PTSD patients and healthy controls. Twelve medication-free participants with a current diagnosis of PTSD and 15 matched healthy controls underwent positron emission tomography (PET) imaging using [11C] flumazenil. Structural magnetic resonance imaging (MRI) scans were obtained and co-registered to the PET images to permit co-location of neuroanatomical structures in the lower resolution PET image data. Compared to healthy controls, PTSD patients exhibited increased BZD binding in the caudal anterior cingulate cortex and precuneus (p's < 0.05). Severity of PTSD symptoms positively correlated with BZD binding in the left mid- and anterior insular cortices. This study extends previous findings by suggesting that central BZD receptor system involvement in PTSD includes portions of the default mode and salience networks, along with insular regions that support interoception and autonomic arousal.


Subject(s)
Cerebral Cortex/metabolism , Receptors, GABA-A/metabolism , Stress Disorders, Post-Traumatic/metabolism , Adult , Carbon Radioisotopes , Cerebral Cortex/diagnostic imaging , Female , Flumazenil/administration & dosage , Flumazenil/pharmacokinetics , Gyrus Cinguli/diagnostic imaging , Gyrus Cinguli/metabolism , Humans , Male , Parietal Lobe/diagnostic imaging , Parietal Lobe/metabolism , Positron-Emission Tomography , Stress Disorders, Post-Traumatic/diagnostic imaging
3.
Bipolar Disord ; 17(7): 743-52, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26477793

ABSTRACT

OBJECTIVES: The aim of the present study was to measure brain phosphorus-31 magnetic resonance spectroscopy ((31) P MRS) metabolite levels and the creatine kinase reaction forward rate constant (kf ) in subjects with bipolar disorder (BD). METHODS: Subjects with bipolar euthymia (n = 14) or depression (n = 11) were recruited. Healthy comparison subjects (HC) (n = 23) were recruited and matched to subjects with BD on age, gender, and educational level. All studies were performed on a 3-Tesla clinical magnetic resonance imaging system using a (31) P/(1) H double-tuned volume head coil. (31) P spectra were acquired without (1) H-decoupling using magnetization-transfer image-selected in vivo spectroscopy. Metabolite ratios from a brain region that includes the frontal lobe, corpus callosum, thalamus, and occipital lobe are expressed as a percentage of the total phosphorus (TP) signal. Brain pH was also investigated. RESULTS: Beta-nucleoside-triphosphate (ß-NTP/TP) in subjects with bipolar depression was positively correlated with kf (p = 0.039, r(2) = 0.39); similar correlations were not observed in bipolar euthymia or HC. In addition, no differences in kf and brain pH were observed among the three diagnostic groups. A decrease in the ratio of phosphomonoesters to phosphodiesters (PME/PDE) was observed in subjects with bipolar depression relative to HC (p = 0.032). We also observed a trend toward an inverse correlation in bipolar depression characterized by decreased phosphocreatine and increased depression severity. CONCLUSIONS: In our sample, kf was not altered in the euthymic or depressed mood state in BD. However, decreased PME/PDE in subjects with bipolar depression was consistent with differences in membrane turnover. These data provide preliminary support for alterations in phospholipid metabolism and mitochondrial function in bipolar depression.


Subject(s)
Bipolar Disorder , Corpus Callosum/metabolism , Depression/metabolism , Frontal Lobe/metabolism , Phosphocreatine/metabolism , Thalamus/metabolism , Adult , Bipolar Disorder/diagnosis , Bipolar Disorder/metabolism , Bipolar Disorder/psychology , Depression/diagnosis , Female , Humans , Magnetic Resonance Imaging/methods , Magnetic Resonance Spectroscopy/methods , Male , Mitochondria/metabolism , Phospholipids/metabolism , Phosphorus Isotopes/pharmacology , Psychiatric Status Rating Scales
4.
Psychiatry Res ; 222(3): 149-56, 2014 Jun 30.
Article in English | MEDLINE | ID: mdl-24768210

ABSTRACT

Normal brain activity is associated with task-related pH changes. Although central nervous system syndromes associated with significant acidosis and alkalosis are well understood, the effects of less dramatic and chronic changes in brain pH are uncertain. One environmental factor known to alter brain pH is the extreme, acute change in altitude encountered by mountaineers. However, the effect of long-term exposure to moderate altitude has not been studied. The aim of this two-site study was to measure brain intracellular pH and phosphate-bearing metabolite levels at two altitudes in healthy volunteers, using phosphorus-31 magnetic resonance spectroscopy ((31)P-MRS). Increased brain pH and reduced inorganic phosphate (Pi) levels were found in healthy subjects who were long-term residents of Salt Lake City, UT (4720ft/1438m), compared with residents of Belmont, MA (20ft/6m). Brain intracellular pH at the altitude of 4720ft was more alkaline than that observed near sea level. In addition, the ratio of inorganic phosphate to total phosphate signal also shifted toward lower values in the Salt Lake City region compared with the Belmont area. These results suggest that long-term residence at moderate altitude is associated with brain chemical changes.


Subject(s)
Altitude , Brain/metabolism , Phosphates/metabolism , Adult , Contrast Media , Female , Humans , Hydrogen-Ion Concentration , Magnetic Resonance Spectroscopy/methods , Male , Massachusetts , Phosphorus/metabolism , Phosphorus Isotopes , Reference Values , Utah
5.
Bipolar Disord ; 16(2): 119-28, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24103187

ABSTRACT

OBJECTIVES: Ketamine, an N-methyl d-aspartate (NMDA) antagonist, has rapid antidepressant effects in depressed subjects with bipolar disorder (BD). Evidence supports a role for the glutamatergic system in the pathophysiology of BD. This double-blind, randomized, cross-over study sought to determine cerebral metabolic correlates of antidepressant response to ketamine. METHODS: Twenty-one subjects with BD currently in a depressed state underwent [(18) F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging after receiving a placebo infusion as well as after receiving a ketamine infusion. Metabolism was compared between ketamine and placebo infusions, and correlated with clinical response. Regional metabolic rate of glucose (rMRGlu) in regions of interest (ROIs) and Montgomery-Åsberg Depression Rating Scale (MADRS) scores were the main outcome measures. RESULTS: The study found that change in metabolism between sessions was significantly correlated with percentage change in MADRS scores in the right ventral striatum; subjects who showed the greatest improvement had the largest metabolic increase after ketamine infusion compared to placebo. In a voxel-wise analysis, subjects with BD had significantly lower glucose metabolism in the left hippocampus following the ketamine infusion than following the placebo infusion. In addition, metabolism in the subgenual anterior cingulate cortex (ACC) following the placebo infusion was positively correlated with percentage improvement in MADRS score following the ketamine infusion. CONCLUSIONS: Taken together, the results suggest that higher activity in the subgenual ACC may predict antidepressant response to ketamine. Ketamine administration altered glucose metabolism in areas known to be involved in mood disorders; these alterations may partially underlie ketamine's mechanism of action.


Subject(s)
Antidepressive Agents/therapeutic use , Bipolar Disorder/drug therapy , Bipolar Disorder/pathology , Brain Mapping , Brain/drug effects , Ketamine/therapeutic use , Adolescent , Adult , Aged , Bipolar Disorder/classification , Brain/diagnostic imaging , Brain/pathology , Cross-Over Studies , Double-Blind Method , Female , Humans , Male , Middle Aged , Positron-Emission Tomography , Psychiatric Status Rating Scales , Treatment Outcome , Young Adult
6.
Eur Neuropsychopharmacol ; 23(12): 1708-13, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24071367

ABSTRACT

The γ-aminobutyric acid (GABA) system has been proposed as a target for novel antidepressant and anxiolytic treatments. Emerging evidence suggests that gabapentin (GBP), an anticonvulsant drug that significantly increases brain GABA levels, is effective in the treatment of anxiety disorders. The current study was designed to measure prefrontal and occipital GABA levels in medication-free healthy subjects after taking 0mg, 150mg and 300mg GBP. Subjects were scanned on a 3T scanner using a transmit-receive head coil that provided a relatively homogenous radiofrequency field to obtain spectroscopy measurement in the medial prefrontal (MPFC) and occipital cortex (OCC). There was no dose-dependent effect of GBP on GABA levels in the OCC or MPFC. There was also no effect on Glx, choline or N-acetyl-aspartate concentrations. The previously reported finding of increased GABA levels after GBP treatment is not evident for healthy subjects at the dose of 150 and 300mg. As a result, if subjects are scanned on a 3T scanner, low dose GPB is not useful as an experimental challenge agent on the GABA system.


Subject(s)
Amines/pharmacology , Anticonvulsants/pharmacology , Cyclohexanecarboxylic Acids/pharmacology , Occipital Lobe/drug effects , Prefrontal Cortex/drug effects , gamma-Aminobutyric Acid/metabolism , Adult , Analysis of Variance , Aspartic Acid/analogs & derivatives , Aspartic Acid/metabolism , Choline/metabolism , Dose-Response Relationship, Drug , Female , Gabapentin , Glutamic Acid/metabolism , Humans , Magnetic Resonance Spectroscopy , Male , Middle Aged , Occipital Lobe/metabolism , Prefrontal Cortex/metabolism , Young Adult , gamma-Aminobutyric Acid/pharmacology
7.
J Psychopharmacol ; 27(10): 894-902, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23926239

ABSTRACT

Abnormal serotonin type 1A (5-HT1A) receptor function and binding have been implicated in the pathophysiology of mood disorders. Preclinical studies have consistently shown that stress decreases the gene expression of 5-HT1A receptors in experimental animals, and that the associated increase in hormone secretion plays a crucial role in mediating this effect. Chronic administration of the mood stabilizers lithium and divalproex (valproate semisodium) reduces glucocorticoid signaling and function in the hippocampus. Lithium has further been shown to enhance 5-HT1A receptor function. To assess whether these effects translate to human subject with bipolar disorder (BD), positron emission tomography (PET) and [18F]trans-4-fluoro-N-(2-[4-(2-methoxyphenyl) piperazino]-ethyl)-N-(2-pyridyl) cyclohexanecarboxamide ([(18)F]FCWAY) were used to acquire PET images of 5-HT1A receptor binding in 10 subjects with BD, before and after treatment with lithium or divalproex. Mean 5-HT1A binding potential (BPP) significantly increased following mood stabilizer treatment, most prominently in the mesiotemporal cortex (hippocampus plus amygdala). When mood state was also controlled for, treatment was associated with increases in BPP in widespread cortical areas. These preliminary findings are consistent with the hypothesis that these mood stabilizers enhance 5-HT1A receptor expression in BD, which may underscore an important component of these agents' mechanism of action.


Subject(s)
Bipolar Disorder/drug therapy , Bipolar Disorder/metabolism , Lithium Compounds/pharmacology , Lithium Compounds/therapeutic use , Receptor, Serotonin, 5-HT1A/metabolism , Valproic Acid/pharmacology , Valproic Acid/therapeutic use , Adult , Amygdala/diagnostic imaging , Amygdala/drug effects , Amygdala/metabolism , Bipolar Disorder/diagnostic imaging , Female , Functional Neuroimaging , Hippocampus/diagnostic imaging , Hippocampus/drug effects , Hippocampus/metabolism , Humans , Male , Middle Aged , Radioligand Assay , Radionuclide Imaging , Young Adult
8.
Biol Psychiatry ; 73(12): 1213-21, 2013 Jun 15.
Article in English | MEDLINE | ID: mdl-23540908

ABSTRACT

BACKGROUND: Multiple lines of evidence support a role for the glutamatergic system in the pathophysiology of major depressive disorder (MDD). Ketamine, an N-methyl-D-aspartate antagonist, rapidly improves depressive symptoms in individuals with treatment-resistant depression. The neural mechanisms underlying this effect remain unknown. METHODS: In this preliminary study, 20 unmedicated participants with treatment-resistant MDD underwent positron emission tomography to measure regional cerebral glucose metabolism at baseline and following ketamine infusion (single dose of .5mg/kg intravenous over 40minutes). Metabolic data were compared between conditions using a combination of region-of-interest and voxelwise analyses, and differences were correlated with the associated antidepressant response. RESULTS: Whole-brain metabolism did not change significantly following ketamine. Regional metabolism decreased significantly under ketamine in the habenula, insula, and ventrolateral and dorsolateral prefrontal cortices of the right hemisphere. Metabolism increased postketamine in bilateral occipital, right sensorimotor, left parahippocampal, and left inferior parietal cortices. Improvement in depression ratings correlated directly with change in metabolism in right superior and middle temporal gyri. Conversely, clinical improvement correlated inversely with metabolic changes in right parahippocampal gyrus and temporoparietal cortex. CONCLUSIONS: Although preliminary, these results indicate that treatment-resistant MDD subjects showed decreased metabolism in the right habenula and the extended medial and orbital prefrontal networks in association with rapid antidepressant response to ketamine. Conversely, metabolism increased in sensory association cortices, conceivably related to the illusory phenomena sometimes experienced with ketamine. Further studies are needed to elucidate how these functional anatomical changes relate to the molecular mechanisms underlying ketamine's rapid antidepressant effects.


Subject(s)
Antidepressive Agents/therapeutic use , Brain Mapping , Brain , Depressive Disorder, Treatment-Resistant/drug therapy , Ketamine/therapeutic use , Positron-Emission Tomography , Adult , Brain/blood supply , Brain/diagnostic imaging , Brain/drug effects , Female , Fluorodeoxyglucose F18 , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Middle Aged , Oxygen/blood
9.
Eur Neuropsychopharmacol ; 23(8): 822-9, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23434290

ABSTRACT

Multiple lines of evidence suggest that serotonin type 1A (5-HT(1A)) receptor dysfunction is involved in the pathophysiology of mood disorders, and that alterations in 5-HT(1A) receptor function play a role in the mechanisms of antidepressant and mood stabilizer treatment. The literature is in disagreement, however, as to whether 5-HT(1A) receptor binding abnormalities exist in bipolar disorder (BD). We acquired PET images of 5-HT(1A) receptor binding in 26 unmedicated BD subjects and 37 healthy controls using [¹8F]FCWAY, a highly selective 5-HT(1A) receptor radio-ligand. The mean 5-HT(1A) receptor binding potential (BP(P)) was significantly lower in BD subjects compared to controls in cortical regions where 5-HT(1A) receptors are expressed post-synaptically, most prominently in the mesiotemporal cortex. Post-hoc assessments involving other receptor specific binding parameters suggested that this difference particularly affected the females with BD. The mean BPP did not differ between groups in the raphe nucleus, however, where 5-HT(1A) receptors are predominantly expressed pre-synaptically. Across subjects the BPP in the mesiotemporal cortex was inversely correlated with trough plasma cortisol levels, consistent with preclinical literature indicating that hippocampal 5-HT(1A) receptor expression is inhibited by glucocorticoid receptor stimulation. These findings suggest that 5-HT(1A) receptor binding is abnormally reduced in BD, and this abnormality may particularly involve the postsynaptic 5-HT(1A) receptor system of individuals with a tendency toward cortisol hypersecretion.


Subject(s)
Bipolar Disorder/metabolism , Cerebral Cortex/metabolism , Down-Regulation , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Post-Synaptic Density/metabolism , Receptor, Serotonin, 5-HT1A/metabolism , Adrenal Cortex/metabolism , Adrenal Cortex/physiopathology , Adrenocortical Hyperfunction/physiopathology , Adult , Bipolar Disorder/blood , Bipolar Disorder/physiopathology , Diagnostic and Statistical Manual of Mental Disorders , Female , Humans , Hydrocortisone/blood , Hydrocortisone/metabolism , Male , Middle Aged , Positron-Emission Tomography , Radioligand Assay , Sex Characteristics , Young Adult
10.
Int J Neuropsychopharmacol ; 16(4): 733-43, 2013 May.
Article in English | MEDLINE | ID: mdl-22953744

ABSTRACT

The central serotonergic system has been implicated in the pathophysiology of panic disorder (PD) by evidence of abnormally elevated serotonin-turnover, reduced pre- and post-synaptic 5-HT(1A)-receptor sensitivity and binding and clinical improvement during administration of agents that enhance serotonergic transmission. Polymorphisms in genes that putatively influence serotonergic neurotransmission increase the vulnerability for developing PD specifically in males. We tested the hypotheses that serotonin transporter (5-HTT) binding is elevated in PD subjects vs. healthy controls in regions where in vivo evidence exists for both elevated 5-HTT and 5-HT(1A) receptor levels in PD and investigated whether the extent of this difference depends upon gender. Volunteers were out-patients with current PD (n=24) and healthy controls (n=24). The non-displaceable component of 5-HTT binding-potential (BP(ND)) was measured using positron emission tomography and the 5-HTT selective radioligand, [(11)C]DASB. PD severity was assessed using the PD Severity Scale. The 5-HTT-BP(ND) was increased in males with PD relative to male controls in the anterior cingulate cortex (F=8.96, p(FDR)=0.01) and midbrain (F=5.09, p(FDR)=0.03). In contrast, BP(ND) did not differ between females with PD and female controls in any region examined. The finding that 5-HTT-binding is elevated in males but not in females with PD converges with other evidence suggesting that dysfunction within the central serotonergic system exists in PD, and also indicates that such abnormalities are influenced by gender. These findings conceivably may reflect a sexual dimorphism that underlies the greater efficacy of serotonin reuptake inhibitor treatment in females vs. males with PD.


Subject(s)
Brain/metabolism , Panic Disorder/metabolism , Panic Disorder/psychology , Serotonin Plasma Membrane Transport Proteins/metabolism , Sex Characteristics , Adolescent , Adult , Brain/pathology , Female , Humans , Male , Middle Aged , Panic Disorder/diagnosis , Protein Binding/physiology , Young Adult
11.
Sci Rep ; 2: 667, 2012.
Article in English | MEDLINE | ID: mdl-22993692

ABSTRACT

Targeted metabolomics provides an approach to quantify metabolites involved in specific molecular pathways. We applied an electrochemistry-based, targeted metabolomics platform to define changes in tryptophan, tyrosine, purine and related pathways in the depressed and remitted phases of major depressive disorder (MDD). Biochemical profiles in the cerebrospinal fluid of unmedicated depressed (n = 14; dMDD) or remitted MDD subjects (n = 14; rMDD) were compared against those in healthy controls (n = 18; HC). The rMDD group showed differences in tryptophan and tyrosine metabolism relative to the other groups. The rMDD group also had higher methionine levels and larger methionine-to-glutathione ratios than the other groups, implicating methylation and oxidative stress pathways. The dMDD sample showed nonsignificant differences in the same direction in several of the metabolic branches assessed. The reductions in metabolites associated with tryptophan and tyrosine pathways in rMDD may relate to the vulnerability this population shows for developing depressive symptoms under tryptophan or catecholamine depletion.


Subject(s)
Biogenic Monoamines/cerebrospinal fluid , Depressive Disorder, Major/cerebrospinal fluid , Metabolome , Adult , Biosynthetic Pathways , Case-Control Studies , Female , Humans , Male , Middle Aged , Multivariate Analysis , Remission, Spontaneous , Severity of Illness Index
12.
Accid Anal Prev ; 48: 317-25, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22664696

ABSTRACT

Although it is generally expected that wider lines will have a positive effect on vehicle safety, there have not been any convincing evidence based on the crash data analysis, partly because of the lack of relevant data. In this paper, the safety effect of wider edge lines was examined by analyzing crash frequency data for road segments with and without wider edge lines. The data from three states, Kansas, Michigan, and Illinois, have been analyzed. Because of different nature of data from each state, a different statistical analysis approach was employed for each state: an empirical Bayes, before-after analysis of Kansas data, an interrupted time series design and generalized linear segmented regression analysis of Michigan data, and a cross sectional analysis of Illinois data. Although it is well-known that causation is hard to establish based on observational studies, the results from three extensive statistical analyses all point to the same findings. The consistent findings lend support to the positive safety effects of wider edge lines installed on rural, two-lane highways.


Subject(s)
Accident Prevention/methods , Accidents, Traffic/prevention & control , Environment Design , Accidents, Traffic/mortality , Accidents, Traffic/statistics & numerical data , Bayes Theorem , Cross-Sectional Studies , Humans , Illinois , Kansas , Linear Models , Michigan , Rural Population
13.
Neurosci Lett ; 520(1): 1-5, 2012 Jun 27.
Article in English | MEDLINE | ID: mdl-22579817

ABSTRACT

Patents with major depression have evidence of a proinflammatory state with consistent elevations in acute phase proteins and in the levels of inflammatory mediators such as interleukin-6 and tumor necrosis factor-α. We report here a study of the serum levels of immunoglobulin A (IgA) in medication-free patients with major depression in the remitted state (ruMDD). Selective IgA deficiency is the most common form of immunoglobulin abnormality, and is often associated with a higher than expected incidence of proinflammatory and autoimmune phenomena. We measured serum IgG, IgM, and IgA in 28 ruMDD patients and 27 healthy subjects (Ctrl) at 0 (pretreatment), 7, and 24h following sham depletion and tryptophan (TrpD) depletion conducted at least 8 days apart under balanced, randomized, blinded conditions. Immunoglobulins were measured by automated immunonephelometry. Data were analyzed by repeated measures ANOVA with diagnosis as a fixed effect and drug (TrpD vs. sham), and time as repeated measures factors. Serum IgA was consistently lower in ruMDD patients vs. Ctrl at all time points examined (p<0.04 for main effect of diagnosis). Serum IgG and IgM levels did not show significant differences by diagnosis. Medication-free patients with major depression in the remitted state have a significant reduction in serum IgA levels measured on multiple occasions. In the light of the fact that IgA serves many immunomodulatory, anti-inflammatory roles, this finding supports the concept that major depressive illness represents a proinflammatory state.


Subject(s)
Depressive Disorder, Major/immunology , Immunoglobulin A/blood , Adult , Cross-Over Studies , Depressive Disorder, Major/blood , Depressive Disorder, Major/drug therapy , Double-Blind Method , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Male
14.
Sci Rep ; 2: 308, 2012.
Article in English | MEDLINE | ID: mdl-22403745

ABSTRACT

Individuals with major depressive disorder (MDD) display abnormal neurophysiological responses to psychological stress but little is known about their neurophysiological responses to physiological stressors. Using [(15)O-H(2)O] positron emission tomography we assessed whether the regional cerebral blood flow (rCBF) response to arterial cannulation differed between patients with MDD and healthy controls (HCs). Fifty-one MDD patients and 62 HCs were scanned following arterial cannulation and 15 MDD patients and 17 HCs were scanned without arterial cannulation. A region-of-interest analysis showed that a significantly increased rCBF of the anterior cingulate cortex and right amygdala was associated with arterial cannulation in MDD. A whole brain analysis showed increased rCBF of the right post-central gyrus, left temporopolar cortex, and right amygdala during arterial cannulation in MDD patients. The rCBF in the right amygdala was significantly correlated with depression severity. Conceivably, the limbic response to invasive physical stress is greater in MDD subjects than in HCs.


Subject(s)
Catheterization , Cerebrovascular Circulation , Depressive Disorder, Major/physiopathology , Regional Blood Flow , Adult , Depressive Disorder, Major/diagnostic imaging , Female , Humans , Male , Middle Aged , Positron-Emission Tomography
15.
Anxiety Stress Coping ; 25(4): 425-42, 2012 Jul.
Article in English | MEDLINE | ID: mdl-21864204

ABSTRACT

Few studies have addressed whether the use of avoidance-oriented coping strategies is related to the development of panic in patients with panic disorder(PD). Self-report, clinician-rated, and physiological data were collected from 42 individuals who participated in a yohimbine biological challenge study, performed under double-blind, placebo-controlled conditions. Participants included 20 healthy controls and 22 currently symptomatic patients who met DSM-IV-TR diagnostic criteria for PD. Consistent with prediction, patients with PD who had higher perceived efficacy of avoidance-oriented strategies in reducing anxiety-related thoughts reported increased severity in panic symptoms during the yohimbine challenge condition as compared to the placebo. Further, patients with PD who had more fear of cognitive dyscontrol, cardiovascular symptoms, and publicly observable anxiety also reported increased severity in panic symptoms during the challenge. Healthy controls who had more fear of cardiovascular symptoms similarly reported increased severity in panic symptoms during the challenge. No effects were found for heart rate response to the challenge agent. These results provide support for the role of avoidance-oriented coping strategies and fear of anxiety-related symptoms as risk and maintenance factors in the development of panic symptoms, particularly within a biological challenge model.


Subject(s)
Adaptation, Psychological , Adrenergic alpha-2 Receptor Antagonists/pharmacology , Panic Disorder/psychology , Yohimbine/pharmacology , Adult , Brain/physiopathology , Cross-Over Studies , Double-Blind Method , Female , Heart Rate/drug effects , Humans , Interview, Psychological , Male , Middle Aged , Neuroimaging , Panic Disorder/chemically induced , Panic Disorder/physiopathology , Positron-Emission Tomography , Psychiatric Status Rating Scales , Young Adult
16.
J Neuroimmunol ; 222(1-2): 87-9, 2010 May.
Article in English | MEDLINE | ID: mdl-20227114

ABSTRACT

Autoimmune disease and/or autoantibodies have been reported in mood disorder patients. We screened for autoantibodies to glutamic acid decarboxylase (GAD65), thyroid peroxidase (TPO), gastric H+/K+ ATPase (ATP4B), and Ro52 in a psychiatric patient cohort. A 24-year-old woman with major depressive disorder (MDD) with reduced psychomotor activity was identified with unusually high serum GAD65 and Ro52 autoantibody titers. Anti-GAD65 and anti-Ro52 autoantibodies were also elevated in the CSF from this patient. Longitudinal examination revealed a four-fold increase in anti-GAD65 serum antibody titers which correlated with exacerbation of psychomotor symptomatology. These results suggest the possibility that CNS autoimmunity may be responsible for the psychomotor impairment in this MDD patient.


Subject(s)
Autoantibodies/blood , Depressive Disorder, Major/immunology , Glutamate Decarboxylase/immunology , Ribonucleoproteins/immunology , Adult , Autoantibodies/analysis , Autoantibodies/cerebrospinal fluid , Autoimmunity/physiology , Biomarkers/analysis , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Brain/immunology , Brain/metabolism , Brain/physiopathology , Brain Chemistry/immunology , Depressive Disorder, Major/blood , Depressive Disorder, Major/cerebrospinal fluid , Female , Humans , Male , Psychomotor Disorders/blood , Psychomotor Disorders/immunology , Psychomotor Disorders/physiopathology , Up-Regulation/immunology , Young Adult , gamma-Aminobutyric Acid/biosynthesis
17.
Arch Gen Psychiatry ; 65(10): 1166-75, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18838633

ABSTRACT

CONTEXT: The benzodiazepine (BZD) receptor system has been implicated in the pathophysiologic mechanism of panic disorder (PD) by indirect evidence from pharmacological challenge studies and by direct evidence from single-photon emission computed tomography and positron emission tomography neuroimaging studies. However, the results of previous neuroimaging studies are in disagreement, possibly because of experimental design limitations related to sample size, matching between patients and controls, and confounding medication effects. OBJECTIVE: To compare BZD receptor binding between subjects with PD and healthy control subjects. DESIGN: Cross-sectional study for association. SETTING: Psychiatric outpatient clinic of the National Institute of Mental Health. PARTICIPANTS: Fifteen subjects with PD who were naïve to BZD drug exposure and were not receiving other drug treatment, and 18 healthy controls. INTERVENTION: Images of BZD receptor binding were acquired using positron emission tomography and flumazenil tagged with carbon 11. MAIN OUTCOME MEASURES: The BZD receptor binding potential was assessed by a simplified reference tissue-tracer kinetic model. RESULTS: The BZD receptor binding potential was decreased in multiple areas of the frontal, temporal, and parietal cortices and was increased in the hippocampus/parahippocampal region in subjects with PD vs controls. The most significant decrease was located in the dorsal anterolateral prefrontal cortex (DALPFC); the most significant increase, in the hippocampus/parahippocampal gyrus. These abnormalities were not accounted for by comorbid depression. In subjects with PD, the severity of panic and anxiety symptoms correlated positively with BZD receptor binding in the DALPFC but negatively with binding in the hippocampus/parahippocampal gyrus. CONCLUSIONS: These data provide evidence of abnormal BZD-gamma-aminobutyric acid type A receptor binding in PD, suggesting that basal and/or compensatory changes in inhibitory neurotransmission play roles in the pathophysiologic mechanism of PD. They also provide evidence of an impairment of frontal-limbic interaction in the modulation of anxiety responses, consistent with previous functional and structural neuroimaging studies in PD.


Subject(s)
Brain/diagnostic imaging , Carbon Radioisotopes , Flumazenil , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Panic Disorder/diagnostic imaging , Positron-Emission Tomography , Receptors, GABA-A/physiology , Adult , Brain/physiopathology , Brain Mapping , Cerebral Cortex/diagnostic imaging , Cerebral Cortex/physiopathology , Comorbidity , Depressive Disorder, Major/diagnostic imaging , Depressive Disorder, Major/physiopathology , Dominance, Cerebral/physiology , Female , Flumazenil/pharmacokinetics , Gyrus Cinguli/diagnostic imaging , Gyrus Cinguli/physiopathology , Hippocampus/diagnostic imaging , Hippocampus/physiopathology , Humans , Male , Middle Aged , Panic Disorder/physiopathology , Parahippocampal Gyrus/diagnostic imaging , Parahippocampal Gyrus/physiopathology , Reference Values , Software
18.
Arch Gen Psychiatry ; 65(5): 521-31, 2008 May.
Article in English | MEDLINE | ID: mdl-18458204

ABSTRACT

CONTEXT: The pathophysiologic mechanism of major depressive disorder (MDD) has been consistently associated with altered catecholaminergic function, especially with decreased dopamine neurotransmission, by various sources of largely indirect evidence. An instructive paradigm for more directly investigating the relationship between catecholaminergic function and depression has involved the mood response to experimental catecholamine depletion (CD). OBJECTIVES: To determine whether catecholaminergic dysfunction represents a trait abnormality in MDD and to identify brain circuitry abnormalities involved in the pathophysiologic mechanism of MDD. DESIGN: Randomized, double-blind, placebo-controlled, crossover, single-site experimental trial. SETTING: Psychiatric outpatient clinic. PARTICIPANTS: Fifteen unmedicated subjects with MDD in full remission (hereinafter referred to as RMDD subjects) and 13 healthy controls. INTERVENTION: Induction of CD by oral administration of alpha-methylparatyrosine. Sham depletion used identical capsules containing hydrous lactose. MAIN OUTCOME MEASURES: Quantitative positron emission tomography of regional cerebral glucose utilization to study the neural effects of CD and sham depletion. Behavioral assessments included the Montgomery-Asberg Depression Rating Scale and the Snaith-Hamilton Pleasure Scale (anhedonia). RESULTS: Depressive and anhedonic symptoms increased during CD to a greater extent in RMDD subjects than in controls. In both groups, CD increased metabolism in the anteroventral striatum and decreased metabolism in the orbital gyri. In a limbic-cortical-striatal-pallidal-thalamic network previously implicated in MDD, composed of the ventromedial frontal polar cortex, midcingulate and subgenual anterior cingulate cortex, temporopolar cortex, ventral striatum, and thalamus, metabolism increased in RMDD subjects but decreased or remained unchanged in controls. Metabolic changes induced by CD in the left ventromedial frontal polar cortex correlated positively with depressive symptoms, whereas changes in the anteroventral striatum were correlated with anhedonic symptoms. CONCLUSIONS: This study provides direct evidence for catecholaminergic dysfunction as a trait abnormality in MDD. It demonstrates that depressive and anhedonic symptoms as a result of decreased catecholaminergic neurotransmission are related to elevated activity within the limbic-cortical-striatal-pallidal-thalamic circuitry.


Subject(s)
Brain/metabolism , Brain/physiopathology , Catecholamines/antagonists & inhibitors , Catecholamines/deficiency , Depressive Disorder, Major/metabolism , Depressive Disorder, Major/physiopathology , Health Status , Nerve Net/metabolism , Nerve Net/physiopathology , alpha-Methyltyrosine/pharmacology , Adolescent , Adult , Brain/diagnostic imaging , Corpus Striatum/diagnostic imaging , Corpus Striatum/metabolism , Corpus Striatum/physiopathology , Cross-Over Studies , Diagnostic and Statistical Manual of Mental Disorders , Double-Blind Method , Female , Globus Pallidus/diagnostic imaging , Globus Pallidus/metabolism , Globus Pallidus/physiopathology , Glucose/metabolism , Humans , Limbic System/diagnostic imaging , Limbic System/metabolism , Limbic System/physiopathology , Male , Middle Aged , Nerve Net/diagnostic imaging , Positron-Emission Tomography , Prefrontal Cortex/diagnostic imaging , Prefrontal Cortex/metabolism , Prefrontal Cortex/physiopathology , Remission Induction , Thalamus/diagnostic imaging , Thalamus/metabolism , Thalamus/physiopathology , alpha-Methyltyrosine/administration & dosage
19.
Bipolar Disord ; 9(6): 561-70, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17845270

ABSTRACT

OBJECTIVES: Considerable preclinical biochemical and behavioral data suggest that protein kinase C inhibition would bring about antimanic effects. Notably, the structurally highly dissimilar antimanic agents lithium and valproate, when administered in therapeutically relevant paradigms, attenuate protein kinase C [corrected] function. There is currently only one relatively selective protein kinase C inhibitor that crosses the blood-brain barrier available for human use--tamoxifen. Our group recently conducted a single-blind study with tamoxifen in acute mania and found that it significantly decreased manic symptoms within a short period of time (3-7 days). In this study, we investigated whether antimanic effects can be achieved with a protein kinase C inhibitor in subjects with mania. METHODS: In a double-blind, placebo-controlled study, 16 subjects with bipolar disorder, manic or mixed, with or without psychotic features, were randomly assigned to receive tamoxifen (20-140 mg/day; n = 8) or placebo (n = 8) for three weeks. Primary efficacy was assessed by the Young Mania Rating Scale. RESULTS: Subjects on tamoxifen showed significant improvement in mania compared to placebo as early as five days, an effect that remained significant throughout the three-week trial. The effect size for the drug difference was very large (d = 1.08, 95% confidence interval 0.45-1.71) after three weeks (p = 0.001). At study endpoint, response rates were 63% for tamoxifen and 13% for placebo (p = 0.12). CONCLUSIONS: Antimanic effects resulted from a protein kinase C inhibitor; onset occurred within five days. Large, controlled studies with selective protein kinase C inhibitors in acute mania are warranted.


Subject(s)
Bipolar Disorder/drug therapy , Tamoxifen/administration & dosage , Acute Disease , Adolescent , Adult , Bipolar Disorder/enzymology , Bipolar Disorder/physiopathology , Double-Blind Method , Female , Humans , Male , Middle Aged , Pilot Projects , Protein Kinase C/antagonists & inhibitors , Psychiatric Status Rating Scales , Signal Transduction/drug effects , Tamoxifen/adverse effects , Treatment Outcome
20.
Arch Gen Psychiatry ; 63(8): 856-64, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16894061

ABSTRACT

CONTEXT: Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders. OBJECTIVE: To determine whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression. DESIGN: A randomized, placebo-controlled, double-blind crossover study from November 2004 to September 2005. SETTING: Mood Disorders Research Unit at the National Institute of Mental Health. Patients Eighteen subjects with DSM-IV major depression (treatment resistant). INTERVENTIONS: After a 2-week drug-free period, subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart. Subjects were rated at baseline and at 40, 80, 110, and 230 minutes and 1, 2, 3, and 7 days postinfusion. Main Outcome Measure Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale. RESULTS: Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 minutes after injection, which remained significant throughout the following week. The effect size for the drug difference was very large (d = 1.46 [95% confidence interval, 0.91-2.01]) after 24 hours and moderate to large (d = 0.68 [95% confidence interval, 0.13-1.23]) after 1 week. Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion. Thirty-five percent of subjects maintained response for at least 1 week. CONCLUSIONS: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder, Major/drug therapy , Ketamine/therapeutic use , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Adult , Antidepressive Agents/administration & dosage , Cross-Over Studies , Depressive Disorder, Major/psychology , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Drug Resistance , Excitatory Amino Acid Antagonists/administration & dosage , Excitatory Amino Acid Antagonists/therapeutic use , Female , Humans , Infusions, Intravenous , Ketamine/administration & dosage , Male , Middle Aged , Placebos , Psychiatric Status Rating Scales/statistics & numerical data , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...